Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01522/full |
id |
doaj-683915b769cd4d2eaf589f282c0ad7c9 |
---|---|
record_format |
Article |
spelling |
doaj-683915b769cd4d2eaf589f282c0ad7c92020-11-25T00:16:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-01-01910.3389/fphar.2018.01522430580Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric CancerOtília Menyhárt0Otília Menyhárt1Lőrinc Sándor Pongor2Lőrinc Sándor Pongor3Balázs Győrffy4Balázs Győrffy52nd Department of Pediatrics, Semmelweis University, Budapest, HungaryMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary2nd Department of Pediatrics, Semmelweis University, Budapest, HungaryMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary2nd Department of Pediatrics, Semmelweis University, Budapest, HungaryMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, HungaryThe immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed to uncover mutations associated with elevated PD-L1 expression in GC patients. Data from 410 GC patients were available, including the mutational spectrum of 39,916 genes and expression values of 20,500 genes. PD-L1 gene expression was compared to the mutational status of each gene separately by using a Mann-Whitney U-test and a Receiver Operating Characteristic test. Only mutations with a prevalence over 5% were considered. Significance was accepted in cases of p < 1E-05 and a fold change over 1.44. Mutations in 209 genes were associated with increased PD-L1 expression. These mutations were enriched in genes related to microtubule-based movement (p = 3.4E-4), cell adhesion (p = 4.9E-4), response to DNA-damage (p = 6.9E-4), and double-strand break-repair (p = 1.6E-3). Mutations in TTK (p = 8.8E-10, AUC = 0.77), COL7A1 (p = 2.0E-9, AUC = 0.74), KIF15 (p = 2.5E-9, AUC = 0.75), and BDP1 (p = 3.3E-9, AUC = 0.74) had the strongest link to elevated PD-L1 expression. Finally, we established a decision tree based on mutations in PIK3CA, MEF2C, SLC11A1, and KIF15 capable to separate patient sub-cohorts with elevated PD-L1 expression. In summary, we identified mutations associated with elevated PD-L1 expression that facilitate the development of better prognostic biomarkers for GC, and might offer insight into the underlying tumor biology.https://www.frontiersin.org/article/10.3389/fphar.2018.01522/fullimmunotherapystomach cancerimmune checkpoint inhibitorsCD274PIK3CATTK |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Otília Menyhárt Otília Menyhárt Lőrinc Sándor Pongor Lőrinc Sándor Pongor Balázs Győrffy Balázs Győrffy |
spellingShingle |
Otília Menyhárt Otília Menyhárt Lőrinc Sándor Pongor Lőrinc Sándor Pongor Balázs Győrffy Balázs Győrffy Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer Frontiers in Pharmacology immunotherapy stomach cancer immune checkpoint inhibitors CD274 PIK3CA TTK |
author_facet |
Otília Menyhárt Otília Menyhárt Lőrinc Sándor Pongor Lőrinc Sándor Pongor Balázs Győrffy Balázs Győrffy |
author_sort |
Otília Menyhárt |
title |
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer |
title_short |
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer |
title_full |
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer |
title_fullStr |
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer |
title_full_unstemmed |
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer |
title_sort |
mutations defining patient cohorts with elevated pd-l1 expression in gastric cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-01-01 |
description |
The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed to uncover mutations associated with elevated PD-L1 expression in GC patients. Data from 410 GC patients were available, including the mutational spectrum of 39,916 genes and expression values of 20,500 genes. PD-L1 gene expression was compared to the mutational status of each gene separately by using a Mann-Whitney U-test and a Receiver Operating Characteristic test. Only mutations with a prevalence over 5% were considered. Significance was accepted in cases of p < 1E-05 and a fold change over 1.44. Mutations in 209 genes were associated with increased PD-L1 expression. These mutations were enriched in genes related to microtubule-based movement (p = 3.4E-4), cell adhesion (p = 4.9E-4), response to DNA-damage (p = 6.9E-4), and double-strand break-repair (p = 1.6E-3). Mutations in TTK (p = 8.8E-10, AUC = 0.77), COL7A1 (p = 2.0E-9, AUC = 0.74), KIF15 (p = 2.5E-9, AUC = 0.75), and BDP1 (p = 3.3E-9, AUC = 0.74) had the strongest link to elevated PD-L1 expression. Finally, we established a decision tree based on mutations in PIK3CA, MEF2C, SLC11A1, and KIF15 capable to separate patient sub-cohorts with elevated PD-L1 expression. In summary, we identified mutations associated with elevated PD-L1 expression that facilitate the development of better prognostic biomarkers for GC, and might offer insight into the underlying tumor biology. |
topic |
immunotherapy stomach cancer immune checkpoint inhibitors CD274 PIK3CA TTK |
url |
https://www.frontiersin.org/article/10.3389/fphar.2018.01522/full |
work_keys_str_mv |
AT otiliamenyhart mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer AT otiliamenyhart mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer AT lorincsandorpongor mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer AT lorincsandorpongor mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer AT balazsgyorffy mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer AT balazsgyorffy mutationsdefiningpatientcohortswithelevatedpdl1expressioningastriccancer |
_version_ |
1725382305605746688 |